All News

The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.

The J&J booster shot given to health care workers in South Africa between mid-Nov and mid-Dec 2021 was highly effective against Omicron infection.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Pending endorsement from the CDC, adolescents can now get a booster dose of the Pfizer-BioNTech vaccine, as authorized by an amendment to the original FDA EUA for the vaccine.

Cabotegravir extended-release injectable suspension is the first injectable PrEP to receive FDA approval and is given only every 2 months.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

The CDC recommends against the J&J COVID-19 vaccine if Pfizer or Moderna mRNA shots are available while affirming that any COVID vaccine is better than none.

Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

The CDC recommends ASAP use of antivirals in certain high-risk patient groups. Test your memory of who is in those groups with 2 short questions.

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

When is aspirin appropriate in primary ASCVD prevention? Should ezetimibe be added to maximal statin therapy in T2D? This quiz tests your guideline savvy.

In a new retrospective analysis, including smoking history in the 2013 ACC/AHA pooled cohort equations significantly improved ASCVD risk prediction.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Pfizer reported today final results of the phase 2/3 EPIC-HR trial, findings that confirm the investigational drug's 89% efficacy against severe COVID-19 disease.

New research presented at EuroEcho 2021 may help explain why some patients with long COVID-19 experience persistent dyspnea even 1 year after recovery.

COVID-19, in an attempt to bully Flu and potentially gain precious lung space in humans this year, provoked the veteran virus, labeling him as "irrelevant." Flu responds.